price close busi novemb
biomed devic servic
get start buy pt
bottom line reiter buy rate follow anoth except quarter saw
unpreced ww strength includ robust sensor volum ou sale us new
patient add compani continu benefit surg cgm awar
view technolog superior product look forward remain
earli stage roll us continu drive patient awar
dtc invest expect support robust new patient addit
year-end lastli impress execut ou remain earli day strong
 pipelin underpin believ durabl outlook top-lin growth
beyond sum come confid abil
deliv upsid estim guidanc heel new product launch
ye stock expens estim remain bullish
near- long-term product pipelin opportun cgm util permeat
 popul eventu use broader diagnost tool buy
result post revenu y/i top-lin strength
support broad strength across segment includ ou growth xfx
us growth y/i specif us sale benefit increas market
awar accept cgm led acceler medicar
commerci channel manag highlight dtc advertis
includ libr help drive broader patient awar cgm someth
expect continu impact transient
expens relat new manufactur facil transit adjust
ep came cg/street estim
except start manag highlight robust demand new
system support stronger ever market awar accept cgm
biggest constraint near-term patient addit appear manag abil
suppli fulfil new patient demand given unpreced demand new
exist patient addit manag note us patient flow
pharmaci channel lower barrier adopt
patient physician come expens near-term revenu tune
headwind ntm note come broadli in-lin previou
guidanc start year alreadi reflect forward estim
said commentari headwind persist may spook
ou growth xfx ou impress reimburs tailwind
strength key direct sale market manag highlight signific ou
busi make total revenu reiter plan continu
invest ou commerci infrastructur highlight recent entri apac
includ korea japan
decemb analyst day offer lt insight host first investor
confer earli decemb expect gain increment insight
long-term product pipelin well oper plan particularli interest
see plan commerci model market includ intens
non-intens plan integr monet typezero asset
plan oper leverag near/long term
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
guidanc chang estim
given strong increas revenu guidanc
previous manag expect growth support sensor
volum ou expans ww instal base gross margin guidanc
reiter given transitori margin pressur associ transit
product subsequ opex expect increas y/i
y/i previous made follow chang estim
figur summari estim revis
biomed devic servic
resultsactualcg estbeat/miss beat/miss consensusbeat/miss total revenu total gross oper net result categoryactualcg estbeat/missbeat/miss prior yeary/i growthnet sale except ep newold newold newold product
high-growth med-tech comp group current trade mean ev/sal multipl
estim revenu sum maintain price target base
ev/sal multipl appli revenu estim
price target assum cash debt share outstand
figur matrix discount rate impli share price target
biomed devic servic
discount comp ev/sal multipl price metric use ev/sal valuat growth medic devic ev/sal multipl sale share outstand figur dexcom incom statement
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
biomed devic servic
canaccord genuiti estim compani report compani report
biomed devic servic
